share_log

医思健康(02138)拟5250万港元收购Rising Gold Phoenix Limited 90%股权

EC HEALTHCARE (02138) aims to acquire 90% equity of Rising Gold Phoenix Limited for 52.5 million Hong Kong dollars.

Zhitong Finance ·  Dec 10, 2024 23:00

EC HEALTHCARE (02138) announced that on December 10, 2024, the company’s indirect wholly-owned subsidiary BMF Wo...

According to Zhitong Finance APP, EC HEALTHCARE (02138) announced that on December 10, 2024, the company's indirect wholly-owned subsidiary BMF Worldwide Limited intends to acquire approximately 90% of the entire issued share capital of Rising Gold Phoenix Limited from The Cosmetic Care Group Limited for 52.5 million Hong Kong dollars (subject to adjustments).

It is understood that the target company mainly invests in holding companies and operates through its subsidiaries under brands such as BMF, Marie France, Shuyunxun, and Harvard Addhair Technologies to provide (a) customized skincare solutions and professional hair care solutions operated in Hong Kong and Macau; and (b) comprehensive beauty care solutions operated in Hong Kong. Prior to the completion of the acquisition, it is wholly owned by the seller.

The announcement states that to achieve the group’s sustainable development strategic goals, the company continues to actively seek and invest in high-potential business opportunities aiming to create diversified income sources and ensure long-term growth. The recent acquisition represents a key step in this direction, allowing the group to leverage the target group’s expertise and established network in providing specially designed skincare solutions, advanced hair care services, and comprehensive beauty care solutions. These Industries are characterized by strong growth and diversification, holding strategic significance in the Hong Kong market and beyond.

With the target group’s strong customer base and extensive market coverage, the acquisition is expected to significantly enhance the group’s market share while expanding its customer network. By integrating the target group into the company’s leading Medical platform, operational efficiency, cost-saving synergies, and profitability can be improved and enhanced. The group remains committed to leveraging its core strategies, including data-driven sales and marketing, operational efficiency, and advanced digital transformation, to enhance asset value, improve equity returns, and optimize overall financial returns.

In addition, the acquisition includes the acquisition of intellectual property rights of brand names in major markets (including China, Japan, South Korea, UAE, United Kingdom, and Swiss Franc). This strategic move enables the company to expand its presence in the Asia-Pacific and European regions, strengthening its position in high-growth markets and enhancing its competitive advantage on a Global scale.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment